2014 BIO Asia Speakers

  • Recommend
  • Tweet
  • Print
  • Email

2015 speakers to be announced soon. Please check back. 

Below is a list of the 2014 BIO Asia International Conference plenary speakers. 

For additional information about the plenary sessions, click here.

 

Daniel P. Brindle
Senior Director, International Public Affairs & Policy
Pfizer (Asia)

Dan Brindle became Senior Director of International Public Affairs and Policy (Asia) for Pfizer in August 2011. Prior to joining Pfizer, Dan served as Vice President of Government Affairs and Public Policy (Asia) for Eli Lilly and Company.

He held leadership roles for Lilly corporately and in Asia, including: head of Corporate Affairs and Market Access for Lilly’s Emerging Markets; VP of Lilly’s Business Development for Asian Operations; General Manager of Lilly’s Hong Kong / Macau business; and Director for Corporate & Government Affairs for Asia.

He currently serves as the Chair of both the PhRMA Taiwan and PhRMA ASEAN industry task forces. He has also served as an industry advisor to the APEC Life Sciences Initiative, and to government bodies in China, India, Pakistan, Singapore, Taiwan and Thailand. He also helped to develop the Thai Center for the Life Sciences (T-CELS), a government body created to foster innovation and investment in the life sciences industry in Thailand.

Prior to joining Lilly, he served as Legislative Counsel to United States Senator Frank H. Murkowski (Alaska) focusing on East Asia trade and defense issues. He is an attorney, and licensed before the State Bar of California.

Dan was active in developing baseball in Hong Kong, having served as a baseball coach for kids in Hong Kong and on the Board of Directors for the Hong Kong Little League. He is an avid sailor, and scuba-diver, and has participated in several sailing regattas in Asia. He is fluent in Mandarin Chinese, and speaks some Japanese and Taiwanese. He is based in Beijing, China.

The Market for Health Care Innovation in Asia
Coriander Room, 2nd floor
Wednesday, April 9, 2014
9:00-9:55am

Joseph Damond
Senior Vice President International Affairs
Biotechnology Industry Organization (BIO)

Joseph Damond is the Senior Vice President, International Affairs at BIO. Damond has extensive experience in international affairs, trade and economics. He previously served as the Vice President of International Government Relations at Pfizer, Inc.

Prior to his appointment at Pfizer in 2006, Mr. Damond was with the Pharmaceutical Research and Manufacturers of America (PhRMA). As PhRMA’s Deputy Vice President for International Affairs, he was responsible for managing PhRMA’s programs with respect to market access barriers that affect the research-based pharmaceutical industry, with particular focus on pricing and reimbursement policies in developed countries. He joined PhRMA in 2001 as Associate Vice President for Japan and Asia-Pacific at PhRMA’s International Division in Washington.

Before PhRMA, Mr. Damond spent 12 years as a trade negotiator at the Office of the United States Trade Representative, where his last assignment, from 1999-2001, was as Deputy Assistant U.S. Trade Representative for Asia and Pacific/APEC Affairs. During this time, he was also chief negotiator of the historic U.S.-Vietnam Bilateral Trade agreement, completed in July 2000. Prior to his time at USTR, Mr. Damond also spent four years at U.S. Commerce, working on bilateral and multilateral trade negotiations.

Mr. Damond received his Master’s degree from Princeton University’s Woodrow Wilson School of Public and International Affairs in 1985, and his undergraduate degree magna cum laude from Georgetown University, School of Foreign Service, in 1983. He was born and raised in Erie, Pennsylvania, and is a 1979 graduate of Cathedral Preparatory School.

The Rise of Asian IPOs
Tuesday, April 8, 2014
Coriander Room, 2nd floor
9:30-10:25am

Andrew Dickinson
Managing Director
Lazard

Andrew Dickinson joined Lazard's Healthcare Group in 2007 and is a Managing Director based in San Francisco.

Mr. Dickinson has advised on transactions including the acquisition of ViroPharma for Shire, the acquisition of Onyx for Amgen, and the acquisition of Human Genome Sciences for GSK.

Prior to joining Lazard, Mr. Dickinson served as a Senior Legal Advisor to Gilead Sciences and as General Counsel and Vice President of Corporate Development at Myogen, Inc. While at Myogen, Mr. Dickinson managed the strategic process that culminated in Gilead's acquisition of Myogen (2006) and led complex licensing and partnership transactions, including a research and development collaboration with Novartis and a commercial development collaboration with GlaxoSmithKline. Prior to joining Myogen, Mr. Dickinson worked at Cooley Godward LLP and Kirkland & Ellis, LLP where he advised on public and private merger and acquisition transactions as well as debt and equity offerings, private equity fund formations and venture capital financings.

Fitting Partnerships into Global Strategy
Wednesday, April 9, 2014
Grand Ballroom West, 3rd floor
12:00 - 12:55pm

David Flores
President & CEO
BioCentury Publications

David has devoted more than 20 years to developing information products for biotechnology executives and investors. He is a graduate of the University of California at Berkeley and holds an MBA from Stanford University. David is a member of the Advisory Board of the Innovation and New Ventures Office (INVO) at Northwestern University and a member of the Advisory Council of the Keck Graduate Institute of the Applied Life Sciences. He also has served as a member of the Stanford Graduate School of Business Management Board. In 1996, David and BioCentury Co-Founder, Chairman & Editor-in-Chief Karen Bernstein were honored with the Special Recognition Award given by the annual gathering of biotechnology chief executive officers in Laguna Niguel, Calif., citing BioCentury's ongoing contributions to the industry.

The Rise of Asian IPOs
Tuesday, April 8, 2014
Coriander Room, 2nd floor
9:30-10:25am

Ming-Chu Hsu, PhD
Chairman and CEO
TaiGen Biotechnology Co., Ltd.

Dr. Hsu founded TaiGen in 2001, after successfully building the Biotechnology and Pharmaceutical Research Division of the National Health Research Institutes in Taiwan as its founding director. She was also the leader of the Biotechnology/Pharmaceutical Research Program at the National Science and Technology Program in Taiwan, bringing together 62 academic laboratories to conduct mission-oriented research. Before her return to Taiwan in 1998, Dr. Hsu held the position of Research Director, Oncology and Virology at Hoffmann-La Roche, USA, for over 10 years. Prior to that, Dr. Hsu was an assistant professor at Rockefeller University, New York, and a Research Fellow at the California Institute of Technology at Stanford University. Dr. Hsu obtained her Ph.D. degree in biochemistry from the University of Illinois, Urbana-Champaign. Dr. Hsu has extensive experience in establishing both world-class drug discovery teams and clinical development programs.

The Rise of Asian IPOs
Tuesday, April 8, 2014
Coriander Room, 2nd floor
9:30-10:25am

Ryo Kubota, MD, PhD
Chairman, President and CEO
Acucela Inc.

Prior to founding Acucela in 2002, Dr. Kubota worked in the ophthalmology field, including serving as a faculty member at Keio University and at the University of Washington School of Medicine. Dr. Kubota holds an MD and a PhD in medicine from Keio University. He has been board certified in ophthalmology by the Japanese Ophthalmological Association since 1996 and is a member of the American Academy of Ophthalmology, the Association for Research in Vision and Ophthalmology, and the Japanese Ophthalmology Society. Since 2008, Dr. Kubota has been a director of the Japan-America Society of the State of Washington, and since 2013 an advisor to the Japanese Institute for Global Health.

The Rise of Asian IPOs
Tuesday, April 8, 2014
Coriander Room, 2nd floor
9:30-10:25am

Tetsuyuki Maruyama, Ph.D.
General Manager, Pharmaceuticals Research Division
Takeda Pharmaceutical Co., Ltd.

Dr. Tetsuyuki Maruyama is currently Corporate Officer, General Manger and Head of the Pharmaceutical Research Division at Takeda Pharmaceutical Company, Ltd. Trained as a neuroscientist, Tetsuyuki began his career in academics at the University of Minnesota in the US, then later at Cardiff University in the UK, where he was Professor of Neurobiology in the Cardiff School of Biosciences. In 2003, he took his interest in the mechanisms of learning, memory and disorders of cognition into industry, moving to Merck Sharp and Dohme’s Neuroscience Research Centre in the UK. In 2005, Tetsuyuki took the opportunity to move to Singapore as Head of GlaxoSmithKline’s new Centre for Research in Cognitive and Neurodegenerative Disorders, where he stayed until 2010 before moving to Takeda. Now working from Takeda’s new state of the art global research hub the Shonan Research Center near Tokyo, he is responsible for ensuring that Takeda’s global drug discovery teams produce valuable new medicines for unmet medical needs in Takeda’s key therapeutic areas, including CNS, metabolic, cardiovascular, inflammation & immunology, GI & GU, vaccines and cancer (in partnership with Millennium, the Takeda Oncology Company). In 2012, Tetsuyuki became a Japan National and changed his name (previously Paul Chapman).

Fitting Partnerships into Global Strategy
Wednesday, April 9, 2014
Grand Ballroom West, 3rd floor
12:00 - 12:55pm

R. Byron Sigel
Director and Executive Officer, Healthcare Policy and Market Access
Baxter (Japan)

Byron Sigel is responsible for the development and execution of pricing, reimbursement and market access strategies for Baxter Japan. He also leads its government affairs and industrial association management efforts.

Prior to joining Baxter, Byron worked for Eli Lilly Japan for seven years where he held similar responsibilities. Byron began his professional career as diplomat with the U.S. Department of State. He also served at Deputy Assistant U.S. Trade Representative for Japan at USTR from 1995-1999 where he negotiated several bilateral trade agreements between the U.S. and Japan. In addition, Byron held the position of Vice President for Government Affairs, Goldman Sachs (Japan) and headed the Japan Program for The Nature Conservancy (TNC), one of the world’s largest NGOs committed to biodiversity conservation.

Byron received his Ph.D. from Tokyo University, his Master’s degree from Hiroshima University, and his B.S from the University of Michigan

The Market for Health Care Innovation in Asia
Wednesday, April 9, 2014
Coriander Room, 2nd floor
9:00-9:55am

Kurt Tong
Deputy Chief of Mission
U.S. Embassy in Japan

Kurt Tong has served as the Embassy's Deputy Chief of Mission since December 2011. Before coming to Tokyo he was the U.S. Ambassador for Asia-Pacific Economic Cooperation (APEC), managing all aspects of U.S. participation in APEC, while concurrently serving as the Economic Coordinator for the State Department's Bureau of East Asian and Pacific Affairs, organizing bureau-wide efforts on economic policy issues.

Mr. Tong has spent 17 years working and studying in East Asia, including service at the U.S. Embassies in Manila, Tokyo (1996-1999), Beijing and Seoul. He was Director for Korean Affairs at the Department of State from 2008 to 2009. Prior to that, he served as Director for Asian Economic Affairs at the National Security Council from 2006 to 2008. He was a Visiting Scholar at the Tokyo University Faculty of Economics from 1995 to 1996. Prior to joining the Foreign Service in 1990, Mr. Tong was an Associate with the Boston Consulting Group in Tokyo.

Mr. Tong holds a B.A. from the Woodrow Wilson School of Public and International Affairs at Princeton University, and studied graduate-level economics at the U.S. Foreign Service Institute. He has also studied at the Beijing Institute of Education, Inter-University Program for Chinese Language Studies in Taipei, Inter-University Center for Japanese Language Studies in Tokyo, and International Christian University in Tokyo.

Welcome Remarks
Coriander Room, 2nd floor
Tuesday, April 8, 2014
9:00am - 9:25am

George Yeh
President
Taiwan Liposome Company, Ltd. (TLC)

George Yeh joined TLC in 2002 as President. He leads TLC’s operations, responsible for strategic planning, business development, product licensing, and management of corporate funding. In a relatively short period of time, he grew TLC into one of the fastest-growing drug delivery companies in Asia. In 2006, TLC was named top 100 private companies by Red Herring Asia, and shortlisted for Red Herring Global in 2007. TLC is now a public company in Taiwan (ticker number 4152). George also received the “Outstanding Young Innovator Award” in 2008 for his contribution to the biotechnology industry in Taiwan.

George was most recently CFO of Hermes Biosciences, assisting to structure and negotiate technology transfer and license contracts with pharmaceutical companies. Prior to joining Hermes, George was Vice President of AsiaWired Group where he was responsible for procuring corporate funding, strategic planning, and integration of high-level management and financial resources for start-ups. At AsiaWired Group, George successfully assisted Presenter, Calimetrics and other high tech companies with fundraising of over $40M and planned Asian expansion for several US-based companies. Before coming to AsiaWired Group, George was an associate at General Bank, evaluating start-ups and venture capital partnership for debt financing.

George holds a B.A. from the University of California at Berkeley, and a M.A. and a M.B.A. from the University of Michigan at Ann Arbor.

The Rise of Asian IPOs
Tuesday, April 8, 2014
Coriander Room, 2nd floor
9:30-10:25am

Cammy Yuen
Regional Market Access Director
AbbVie

Cammy Yuen is the Regional Market Access Director for AbbVie responsible for the Japan, Asia Pacific markets. Prior to AbbVie’s regional restructure, Cammy was also responsible for market access in Africa and the Middle East, in addition to Asia Pacific. Cammy has been in the pharmaceutical industry for seventeen years focusing on market access, government liaison, reimbursement and pricing of both pharmaceuticals and medical devices. Previous roles include those in Australia and New Zealand, and in the UK for Abbott/AbbVie; sanofi and Janssen/Johnson&Johnson. Cammy holds a Bachelor of Pharmacy degree (Sydney Uni) with post-graduate qualifications in Health Economics (Monash Uni), Drug Evaluation (Melbourne Uni), Management and Marketing (Macquarie Graduate School of Management).

The Market for Health Care Innovation in Asia
Wednesday, April 9, 2014
Coriander Room, 2nd floor
9:00-9:55am